stockportfolio.pro
UroGen Pharma Ltd. (URGN)
Healthcare · Biotechnology · NasdaqGM
UroGen Pharma Ltd. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.53M | $8.16M | $1.13M | $18,000 | $11.80M | $48.04M | $64.36M | $82.71M | $90.40M | $109.79M |
| Gross profit | $17.50M | $7.56M | $-675,000 | $18,000 | $10.79M | $42.88M | $56.70M | $73.35M | $81.52M | $97.34M |
| Net income | $-1.94M | $-20.00M | $-75.66M | $-105.15M | $-128.48M | $-110.82M | $-109.78M | $-102.24M | $-126.87M | $-153.49M |
| Net margin | -11.1% | -245.2% | -6707.2% | -584144.4% | -1088.9% | -230.7% | -170.6% | -123.6% | -140.4% | -139.8% |
Source: UroGen Pharma Ltd. SEC filings (10-K).
Explore 10 years of UroGen Pharma Ltd. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track URGN in your portfolio →
UroGen Pharma Ltd. financial history by metric
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
UroGen Pharma Ltd. — frequently asked questions
What is UroGen Pharma Ltd.'s revenue?
UroGen Pharma Ltd. (URGN) reported revenue of $109.79M for fiscal year 2025, up 21.4% from the prior year, according to its SEC filings.
Is UroGen Pharma Ltd. profitable?
No — URGN reported a net loss of $-153.49M in fiscal 2025.
What is URGN's P/E ratio?
UroGen Pharma Ltd. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is UroGen Pharma Ltd. growing?
URGN's revenue grew at roughly 56.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does UroGen Pharma Ltd. have?
As of fiscal year 2025, URGN carried roughly $122.21M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is UroGen Pharma Ltd.'s gross margin?
URGN's gross margin was 88.7% in fiscal 2025 — gross profit of $97.34M on revenue of $109.79M.
What is UroGen Pharma Ltd.'s market cap?
UroGen Pharma Ltd. (URGN) has a market capitalization of about $1.38B, based on the latest data in our nightly-refreshed cache.
When does UroGen Pharma Ltd.'s fiscal year end?
URGN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from UroGen Pharma Ltd.'s official SEC filings (10-K and 10-Q), covering 10 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.